Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Cynthia X. Ma, MD, PhD, on Clinical Implications of Findings on Neoadjuvant Endocrine Treatment for ER+ HER2– Breast Cancer

Posted: Monday, June 15, 2020

Cynthia X. Ma, MD, PhD, of Washington University, discusses the results of the ALTERNATE trial and whether anastrozole as a neoadjuvant approach is acceptable to most patients. Dr. Ma also addresses the possible value of using a combination of neoadjuvant treatment plus a prognostic tool to determine whether adjuvant treatment may be omitted in a patient with early-stage estrogen receptor–positive, HER2-negative breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.